3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024.
US FDA staff raises no new concerns about Abbott's heart device
The U.S. Food and Drug Administration (FDA) staff reviewers did not raise any new concerns on Friday over the safety and effectiveness of Abbott's heart valve repair device designed for patients wh...
7 Tremendous Dividend Stocks With Double-Digit 5-Year Growth Rates
One mistake investors make when buying dividend stocks is chasing yield. Stocks with the highest yield could be a sign a company is struggling, which could put the yield at risk.
HAE vs. ABT: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Abbott (ABT). But which of these two stocks presents investors with the better value...
2 Stocks to Buy Near Their 52-Week Highs
Abbott Laboratories didn't perform well last year, but it still has bright prospects. Netflix reported strong earnings that point to plenty of growth potential ahead.
2 Healthcare Dividend Kings to Buy and Hold Forever
Abbott Laboratories and Johnson & Johnson have increased their payouts annually for 52 and 61 consecutive years, respectively. Both healthcare companies have long track records of important innovat...
Abbott Labs must face lawsuit over PediaSure height claims
A judge has rejected Abbott Laboratories' effort to dismiss a New York City grandmother's lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition drinks were "clinic...
Could Abbott Labs Be the Next Big Winner in the Billion-Dollar Weight Loss Market?
Novo Nordisk and Eli Lilly have generated billions of dollars in revenue selling weight loss drugs. Abbott Labs is launching a complementary product for those on the weight loss path.
4 med tech stocks with improving prognosis for 2024
Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to dissipa...
Jim Cramer just bought Abbott stock: should you too?
A near 2.0% post-earnings decline in Abbott Laboratories (NYSE: ABT) warrants an investment in the health care giant, says Jim Cramer. Cramer's bullish view on Abbott stock His Charitable Trust bou...
Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?
Here is how Abbott (ABT) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Abbott: Strong R&D Pipeline Continues To Drive Growth; Reiterate 'Strong Buy'
Abbott Laboratories' stock price has risen by 16.6% since October 2023, outperforming the index. The company achieved strong growth in FY23, excluding contributions from COVID testing businesses. A...
Abbott Laboratories on track for new highs in 2024
Abbott Laboratories NYSE: ABT share price fell following its Q4 2023 results, but investors should be cheering the news. The decline is a response to a report that was largely as expected, with the...
Once Slowed By Shutdown, Abbott Labs Says Baby Formula Franchise Back Leading U.S. Market
Less than two years after a headline-grabbing shutdown of a baby formula plant in Michigan that fueled a national crisis, Abbott Laboratories has “reclaimed its previous market-leading position.”
Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise
Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.
Related Companies